Related Experiment Videos
Genetically modified tumour vaccines: an obstacle race to break host tolerance to cancer
S Nawrocki1, P J Wysocki, A Mackiewicz
1Department of Radiation Oncology & Department of Cancer Immunology, USOMS, GreatPoland Cancer Centre, Garbary 15, 61-866 Poznañ, Poland. sergiusz@efis2000.pl
Abstract:
The development of genetically modified tumour vaccines (GMTV) has been prompted by a better understanding of antitumour immune responses and genetic engineering technologies, as well as the identification of numerous tumour antigens (TA) in several malignancies which occasionally induce spontaneous tumour regressions. Cellular vaccines are based on autologous or allogeneic tumour cells genetically engineered to secrete different cytokines, co-stimulatory molecules, or allogeneic HLA molecules in order to provide a strong stimulatory signal together with the presented TA. Another promising approach that is targeted towards breaking immune tolerance to TA, exploits dendritic cells (DC) loaded or genetically modified with TA (and sometimes cytokines). Effective nonviral and viral gene delivery systems have been constructed including a third generation of adenoviral, lentiviral and hybrid vectors. Studies in mice demonstrated that therapeutic, curative immune responses might be elicited by GMTV. Promising results from animal studies are rarely seen in human trials. Several reasons, such as numerous escape mechanisms of slowly evolving spontaneous tumours and immune incompetence of advanced patients, are major concerns. Improved monitoring of immune responses to GMTV is essential to distinguish between responders and non-responders in order to tailor immune therapy strategy to the individual patient.
Insights
Genetically modified tumor vaccines (GMTV) show promise in animal studies by enhancing anti-tumor immune responses. However, translating these findings to human trials faces challenges due to tumor escape mechanisms and patient immune status.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Advances in understanding anti-tumor immunity and genetic engineering have driven the development of genetically modified tumor vaccines (GMTV).
- Identification of tumor antigens (TA) has revealed their potential to induce spontaneous tumor regressions, highlighting targets for therapeutic intervention.
- GMTV strategies aim to overcome immune tolerance to TA and enhance anti-tumor immune responses.
Purpose of the Study:
- To review the development and current status of genetically modified tumor vaccines (GMTV).
- To discuss the challenges and potential strategies for improving GMTV efficacy in human cancer patients.
- To emphasize the importance of monitoring immune responses for personalized GMTV therapy.
Main Methods:
- Genetically engineering autologous or allogeneic tumor cells to secrete cytokines or co-stimulatory molecules.
- Utilizing dendritic cells (DC) loaded or genetically modified with tumor antigens (TA) and cytokines.
- Employing advanced viral and nonviral gene delivery systems, including adenoviral, lentiviral, and hybrid vectors.
Main Results:
- GMTV have demonstrated the potential to elicit therapeutic and curative immune responses in preclinical mouse models.
- Translating promising animal study results into human clinical trials has proven challenging.
- Tumor escape mechanisms and compromised patient immune function in advanced stages are significant hurdles.
Conclusions:
- GMTV represent a promising approach in cancer immunotherapy, with ongoing development in gene delivery and cellular engineering.
- Addressing tumor heterogeneity, immune evasion, and patient-specific factors is crucial for successful clinical translation.
- Personalized immune monitoring is essential to optimize GMTV treatment strategies and improve patient outcomes.